Central catheter-associated Deep vein thrombosis in cancer: clinical course, prophylaxis, treatment
Author
dc.contributor.author
Marín Valdés, Arnaldo Andrés
Author
dc.contributor.author
Bull, Leonardo
Author
dc.contributor.author
Kinzie, Matthew
Author
dc.contributor.author
Andresen, Max
Admission date
dc.date.accessioned
2022-05-26T17:40:57Z
Available date
dc.date.available
2022-05-26T17:40:57Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
BMJ Supportive & Palliative Care 2021;11:371–380
es_ES
Identifier
dc.identifier.other
10.1136/bmjspcare-2019-002106
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/185721
Abstract
dc.description.abstract
The adequate handling of central venous
catheters is a key element in the management
of patients with cancer. Catheter-associated
deep vein thrombosis is frequently observed
in patients with malignant diseases; however,
despite being a common complication among
these patients, objective information concerning
its epidemiology, clinical course, prophylaxis and
treatment strategies is very limited. The reported
incidence of catheter-related
thrombosis (CRT)
is highly variable, depending on symptomatic
events, or if patients are screened for
asymptomatic thrombosis. Several factors have
been identified as potential predisposing factors
for CRT, both technical and pathological aspects.
The anticoagulant of choice is still unclear; while
low-molecular-
weight
heparin is most commonly
used, recent studies assessing the role of direct
oral anticoagulants in the treatment of CRT
show promise as an alternative, but the evidence
remains insufficient and the decision must be
made on a case-by-
case
basis.
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
BMJ
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States